The purpose of this retrospective study is to learn about the real-world effects of the study medicine lorlatinib for the first-line treatment of Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC. The participants included in this study are: * Aged 18 years or more * diagnosed with a/mNSCLC * confirmed with testing for ALK-positive * have started first-line lorlatinib treatment during the patient selection period In this study, the main objectives are to learn the patient characteristics and the real-world treatment pattern of first-line treatment of lorlatinib in China at a real-world setting.
Study Type
OBSERVATIONAL
Enrollment
50
for the treatment of patients with locally advanced or metastatic ALK positive non-small cell lung cancer.
Pfizer
Beijing, China
Age at Start of Lorlatinib Treatment
Number of percentages of patients by age
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Smoking status (if available) at Start of Lorlatinib Treatment
Number of patients by smoking status
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Histology of patients at start of Lorlatinib treatment
Histology of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Eastern Cooperative Oncology Group (ECOG) performance status of patients at Start of Lorlatinib Treatment
number of Eastern Cooperative Oncology Group (ECOG) performance status of patients
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Initial cancer stage at diagnosis of patients prior Start of Lorlatinib Treatment
initial cancer stage of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Current cancer stage at Start of Lorlatinib Treatment
Current cancer stage of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Brain metastases status at Start of Lorlatinib Treatment
Brain metastases status of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Date of initial NSCLC diagnosis
Date of initial NSCLC diagnosis
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Date of a/mNSCLC diagnosis
Date of a/mNSCLC diagnosis of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
ALK-positive diagnosis prior to Start of Lorlatinib Treatment
Date of patients with ALK-positive diagnosis
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Gene testing method and results prior to initiation of lorlatinib treatment
Gene testing method and results of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Date of brain metastases diagnosis prior to initiation of lorlatinib treatment
number and date of brain metastases diagnosis of patients for whom had BM prior lorlatinib treatment
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Presence of comorbidities at Start of Lorlatinib Treatment
Presence of comorbidities of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Concomitant therapies at Start of Lorlatinib Treatment
Concomitant therapies of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Date of lorlatinib initiation
Date of Lorlatinib first prescription were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Initial lorlatinib dose at Start of Lorlatinib Treatment
Initial lorlatinib dose for patients receiving Lorlatinb treatment were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Dose adjustments when patients were prescribed with Lorlatinib Treatment
Dose adjustments of Lorlatinib Treatment and Date were reported in this outcome measure
Time frame: From the date of initiation of lorlatinib treatment to the date of treatment dose adjustments, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Gender at Start of Lorlatinib Treatment
Number of patients by gender
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Weight at Start of Lorlatinib Treatment
Number of patients by weight
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Height at Start of Lorlatinib Treatment
Number of patients by height
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Body mass index (BMI) at Start of Lorlatinib Treatment
Number of patients by BMI
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Time to Discontinuation (TTD) in 1 L lorlatinib patients
Time to Discontinuation (TTD) was the time from the date of initiation of Lorlatinib Treatment to date if the permanent cessation of lorlatinib due to any reasons, including progression, adverse events, patient decision, or physician recommendation. TTD will be analyzed using Kaplan-Meier survival analysis.
Time frame: From the date of first lorlatinib dose until permanent discontinuation of treatment for any cause, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Last dose for Patients who are still on the Lorlatinib first line treatment
Last dose for Patients who are still on the therapy were reported in this outcome measure
Time frame: the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Treatment switching to other ALK TKls from Lorlatinib Treatment
Treatment switching to other ALK TKls was switching from lorlatinib to another ALK-TKIs due to any reasons. The Name of treatment regimen, Date of treatment switch and Duration of each switched regimen were recorded in this outcome measure.
Time frame: From the date of initiation of other ALK TKIs to the study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
1L lorlatinib resistance mechanism (if applicable)
Characterization of acquired resistance mechanisms to first-line lorlatinib, including on-target ALK alterations and off-target/bypass pathway activations, as identified at disease progression.
Time frame: From the date of initiation of lorlatinib treatment to the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Treatment switching to subsequence treatment from 1L Lorlatinib Treatment
Treatment switching to subsequence treatment was switching from lorlatinib to another systemic therapy due to treatment failure caused by progression, intolerance, or physician decision. It was recorded in this outcome measure.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: From the date of initiation of subsequent other treatment to the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Medical Costs during lorlatinib treatment period
Medical Costs during lorlatinib treatment period for patients were reported in this outcome measure, inducing drug costs, hospitalization costs, outpatient cost, and ect.
Time frame: From the date of first lorlatinib dose until permanent discontinuation of treatment for any cause, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Brain metastases progression and date of patients receiving Lorlatinib treatment
Brain metastases progression was radiological confirmation of new or worsening intracranial lesions.
Time frame: From the date of initiation of lorlatinib treatment to the date of BM progression, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Death (if applicable) of patients receiving Lorlatinib for the first-line treatment
percentage of Deaths (and date if applicable) of patients
Time frame: From the date of initiation of lorlatinib treatment to the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
The cumulative incidence rate of BM of patients receiving Lorlatinib for the first-line treatment
Percentage of number of patients with BM
Time frame: From the date of initiation of lorlatinib treatment to the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).